Evaluating Neostigmine Effect on Reducing Gastric Residual Volume as Compared With Metoclopramide and Ondansetron

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

One big problem in mechanically ventilated ICU patients is delayed gastric emptying. Delayed gastric emptying in these patients, causes intolerance and high gastric residual volume (GRV) that can lead to abdominal distention, vomiting, increased aspiration risk and consequently increased the length of hospital stay.

In this study, investigators will evaluate Neostigmine's effect in reducing GRV in mechanically ventilated patients and compare its effect with metoclopramide and Ondansetron

.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Treatments: Metoclopramide; Neostigmine; Ondansetron

Criteria

Inclusion Criteria:

• Mechanically ventilated ICU patients

• With nasogastric tube feeding

• Gastric Residual Volume >120 mL (3hours after the last gavage)

Exclusion Criteria:

• History of diabetes

• Heart block

• Bradycardia (heart rate <60/min)

• Systolic blood pressure less than 90 mm Hg

• Renal insufficiency

• Using any prokinetic agents such as erythromycin or cisapride within 8 hours before study initiation

• Recent surgery (10 days or less) on the stomach or digestive system

• pregnancy and lactation

• Occurrence of extrapyramidal side effects

• Gastrointestinal (GI) bleeding